Skip to main content
Clinical Trials/JPRN-jRCT1041190019
JPRN-jRCT1041190019
Suspended
Phase 2

A phase II randomized clinical trial to determine the effectiveness of goreisan and saireito for lower limb lymphedema in women treated for gynecologic cancer

Kajiyama Hiroaki0 sites40 target enrollmentApril 18, 2019

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
ower Limb Lymphedema
Sponsor
Kajiyama Hiroaki
Enrollment
40
Status
Suspended
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 18, 2019
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Kajiyama Hiroaki

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients who underwent uterine malignancy surgery including retroperitoneal lymph node dissection or surgical operation of the uterine appendix malignant tumor by preoperative diagnosis of gynecological malignancy
  • 2\) Patients diagnosed with secondary lymphedema in 1\)
  • 3\) Patients with ECOG\-PS 0 or 1
  • 4\) Patients whose main organ functions are adequately maintained
  • (A) White blood cell count 3,500 / mm 3 12 000 / mm 3
  • (B) Number of neutrophils 1,500 / mm 3
  • (C) Number of platelets 100,000 / mm 3
  • (D) Hb 9\.0 g / dL
  • (E) AST,ALT 100 IU / L
  • (F) Creatinine 1\.2 mg / dL

Exclusion Criteria

  • 1\) Patients who are allergic to the ingredients of traditional Chinese medicine or goriso\-san/saireito
  • 2\) Patients with severe complications (heart failure, renal failure, liver failure, hypoactive nutrition etc.) and severe mental illness
  • 3\) Patients whose oral ingestion is impossible
  • 4\) Patients diagnosed with primary lymphedema
  • 5\) Patients with lower extremity vein thrombosis
  • 6\) In addition, patients judged unsuitable for doctors to safely carry out this study

Outcomes

Primary Outcomes

Not specified

Similar Trials